BMY-25271
Modify Date: 2024-01-23 01:13:49
BMY-25271 structure
|
Common Name | BMY-25271 | ||
|---|---|---|---|---|
| CAS Number | 78441-82-4 | Molecular Weight | 329.44200 | |
| Density | 1.55g/cm3 | Boiling Point | N/A | |
| Molecular Formula | C12H19N5O2S2 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of BMY-25271BMY-25271 is a histamine H2 receptor antagonist. |
| Name | 3-N-[2-[[5-[(dimethylamino)methyl]furan-2-yl]methylsulfanyl]ethyl]-1-oxo-1,2,5-thiadiazole-3,4-diamine |
|---|---|
| Synonym | More Synonyms |
| Description | BMY-25271 is a histamine H2 receptor antagonist. |
|---|---|
| Related Catalog | |
| Target |
Histamine H2 receptor[1] |
| In Vivo | BMY-25271 is a histamine H2 receptor antagonist. The dose response curves are parallel and oral ED50 values derived from probit analysis are 0.093, 0.97 and 6.9 mg/kg for BMY-25271, ranitidine and cimetidine, respectively. BMY-25271, therefore, is about 10 and 74 times more potent than ranitidine and cimetidine, respectively. Pretreatment with the highest dose of BMY-25271 does not significantly affect the absorption of aspirin or the formation of its major metabolite, salicylic acid[1]. |
| Animal Admin | Five beagle dogs are used in this study. Vehicle or BMY-25271 (0.4 mg/kg) is administered orally 1 h before aspirin (100 mg/kg). Blood samples are collected from the jugular vein just before aspirin administration and 30, 60, 90 and 120 min after aspirin administration. One week later, the dogs are crossed over, and the study is repeated[1]. |
| References |
| Density | 1.55g/cm3 |
|---|---|
| Molecular Formula | C12H19N5O2S2 |
| Molecular Weight | 329.44200 |
| Exact Mass | 329.09800 |
| PSA | 144.28000 |
| LogP | 2.65560 |
| Index of Refraction | 1.828 |
| Storage condition | 2-8℃ |
![2-[([5-[(Dimethylamino)methyl]-2-furyl]methyl)thio]ethan-1-amine structure](https://www.chemsrc.com/caspic/314/66356-53-4.png)
| Precursor 2 | |
|---|---|
| DownStream 0 | |
| BMY-25271 |